CM
PDSB icon

Caption Management’s PDS Biotechnology PDSB Stock Holding History

Caption Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,500
Closed -$105K – 1737
2024
Q3 		$105K Buy
+27,500
New +$91.8K ﹤0.01% 1128
2024
Q1 		– Sell
-50,000
Closed -$249K – 1573
2023
Q4 		$249K Buy
+50,000
New +$249K ﹤0.01% 1087

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Caption Management's PDSB Position: Q1 2024 in Review

Caption Management sold out of PDS Biotechnology (PDSB) in Q1 2024, closing a stake of 8,181 shares — an estimated $40.7K sold.

Caption Management first reported a position in PDSB in Q4 2023 and held it in 1 quarter. The position peaked at $40.7K in Q4 2023. 72 funds tracked by Wall St. Rank hold PDSB as of Q1 2024.

  • Caption Management reported no remaining PDS Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Caption Management sold 8,181 PDS Biotechnology shares in Q1 2024, an estimated $40.7K.
  • Caption Management first reported a position in PDS Biotechnology in Q4 2023 and held it in 1 quarter.
  • Caption Management's PDS Biotechnology position peaked at $40.7K in Q4 2023.
  • 72 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.